
OBIO Stock Forecast & Price Target
OBIO Analyst Ratings
Bulls say
Orchestra BioMed Hldgs is accelerating high-impact biomedical technologies to patients through partnerships with medical device companies, highlighted by their flagship product candidates Atrioventricular Interval Modulation (AVIM) Therapy for hypertension and Virtue Sirolimus AngioInfusion Balloon for arterial disease. They are focused on completing enrollment in their BACKBEAT study by 3Q26 and expect FDA approval and potential breakthrough designation to expand the target patient population. While the company faces commercialization risks, they have a strong cash balance and partnerships with industry leaders to support their product launches.
Bears say
Orchestra BioMed Hldgs is a high-risk investment with a negative outlook due to limited human clinical data, potential for failure of product candidates in clinical trials, and dependence on partnerships for commercialization. Its valuation of $595 million is based on a discounted cash flow analysis and assumes a probability of success of 65% and 40% for its product candidates. Risks to achieving the price target include potential dilution, regulatory delays or denials, and the need for additional funding.
This aggregate rating is based on analysts' research of Orchestra BioMed Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
OBIO Analyst Forecast & Price Prediction
Start investing in OBIO
Order type
Buy in
Order amount
Est. shares
0 shares